CN111567661A - Composite gel candy and preparation method thereof - Google Patents
Composite gel candy and preparation method thereof Download PDFInfo
- Publication number
- CN111567661A CN111567661A CN202010490046.1A CN202010490046A CN111567661A CN 111567661 A CN111567661 A CN 111567661A CN 202010490046 A CN202010490046 A CN 202010490046A CN 111567661 A CN111567661 A CN 111567661A
- Authority
- CN
- China
- Prior art keywords
- parts
- oil
- stirring
- mixing
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000009508 confectionery Nutrition 0.000 title claims abstract description 101
- 239000002131 composite material Substances 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 235000014620 theaflavin Nutrition 0.000 claims abstract description 47
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 claims abstract description 44
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 claims abstract description 44
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 claims abstract description 44
- 229940026509 theaflavin Drugs 0.000 claims abstract description 44
- 239000002775 capsule Substances 0.000 claims abstract description 41
- 238000000034 method Methods 0.000 claims abstract description 27
- 239000000499 gel Substances 0.000 claims description 87
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 69
- 238000002156 mixing Methods 0.000 claims description 62
- 238000003756 stirring Methods 0.000 claims description 62
- 239000007788 liquid Substances 0.000 claims description 60
- 239000003921 oil Substances 0.000 claims description 45
- 235000019198 oils Nutrition 0.000 claims description 45
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 41
- 235000005487 catechin Nutrition 0.000 claims description 41
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 41
- 229950001002 cianidanol Drugs 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 235000013871 bee wax Nutrition 0.000 claims description 32
- 239000012166 beeswax Substances 0.000 claims description 32
- 239000010495 camellia oil Substances 0.000 claims description 32
- 238000010438 heat treatment Methods 0.000 claims description 32
- 239000008213 purified water Substances 0.000 claims description 32
- 239000003813 safflower oil Substances 0.000 claims description 30
- 239000010649 ginger oil Substances 0.000 claims description 27
- 239000010668 rosemary oil Substances 0.000 claims description 26
- 229940058206 rosemary oil Drugs 0.000 claims description 26
- 108010010803 Gelatin Proteins 0.000 claims description 25
- 235000019495 Pecan oil Nutrition 0.000 claims description 25
- 239000008273 gelatin Substances 0.000 claims description 25
- 229920000159 gelatin Polymers 0.000 claims description 25
- 235000019322 gelatine Nutrition 0.000 claims description 25
- 235000011852 gelatine desserts Nutrition 0.000 claims description 25
- 235000021388 linseed oil Nutrition 0.000 claims description 25
- 239000000944 linseed oil Substances 0.000 claims description 25
- 239000010470 pecan oil Substances 0.000 claims description 25
- 238000001035 drying Methods 0.000 claims description 24
- 241000949456 Zanthoxylum Species 0.000 claims description 23
- 239000000845 maltitol Substances 0.000 claims description 23
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 23
- 229940035436 maltitol Drugs 0.000 claims description 23
- 235000010449 maltitol Nutrition 0.000 claims description 23
- 239000000843 powder Substances 0.000 claims description 20
- 238000003825 pressing Methods 0.000 claims description 16
- 239000002994 raw material Substances 0.000 claims description 13
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 10
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 10
- 238000005096 rolling process Methods 0.000 claims description 10
- 238000007873 sieving Methods 0.000 claims description 10
- 238000009423 ventilation Methods 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- 238000007599 discharging Methods 0.000 claims description 9
- 238000007493 shaping process Methods 0.000 claims description 6
- 238000009835 boiling Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 abstract description 33
- 235000020661 alpha-linolenic acid Nutrition 0.000 abstract description 19
- 229960004488 linolenic acid Drugs 0.000 abstract description 19
- 230000008569 process Effects 0.000 abstract description 17
- 230000002401 inhibitory effect Effects 0.000 abstract description 16
- 206010061218 Inflammation Diseases 0.000 abstract description 13
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 abstract description 13
- 230000004054 inflammatory process Effects 0.000 abstract description 13
- 235000020778 linoleic acid Nutrition 0.000 abstract description 13
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 abstract description 13
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 11
- 230000001105 regulatory effect Effects 0.000 abstract description 11
- 238000005728 strengthening Methods 0.000 abstract description 11
- 210000004556 brain Anatomy 0.000 abstract description 9
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 9
- 230000036039 immunity Effects 0.000 abstract description 9
- 230000009286 beneficial effect Effects 0.000 abstract description 8
- 150000008442 polyphenolic compounds Chemical class 0.000 abstract description 8
- 235000013824 polyphenols Nutrition 0.000 abstract description 8
- 241000894006 Bacteria Species 0.000 abstract description 7
- 206010020772 Hypertension Diseases 0.000 abstract description 7
- 241000700605 Viruses Species 0.000 abstract description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 7
- 201000005569 Gout Diseases 0.000 abstract description 5
- 230000003750 conditioning effect Effects 0.000 abstract description 4
- 230000003467 diminishing effect Effects 0.000 abstract description 4
- 238000009776 industrial production Methods 0.000 abstract description 4
- 210000000936 intestine Anatomy 0.000 abstract description 4
- 230000004089 microcirculation Effects 0.000 abstract description 4
- 210000002345 respiratory system Anatomy 0.000 abstract description 4
- 241000712461 unidentified influenza virus Species 0.000 abstract description 4
- 230000001684 chronic effect Effects 0.000 abstract description 3
- 238000013461 design Methods 0.000 abstract description 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 3
- 210000004072 lung Anatomy 0.000 abstract description 2
- 241001122767 Theaceae Species 0.000 abstract 1
- 231100000614 poison Toxicity 0.000 abstract 1
- 239000003440 toxic substance Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 56
- 239000011162 core material Substances 0.000 description 34
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 28
- 230000006870 function Effects 0.000 description 22
- 239000000047 product Substances 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 17
- 210000003491 skin Anatomy 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 229930003427 Vitamin E Natural products 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 14
- 235000019165 vitamin E Nutrition 0.000 description 14
- 229940046009 vitamin E Drugs 0.000 description 14
- 239000011709 vitamin E Substances 0.000 description 14
- 230000001603 reducing effect Effects 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 11
- 244000269722 Thea sinensis Species 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 11
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 10
- 235000019197 fats Nutrition 0.000 description 10
- 210000000987 immune system Anatomy 0.000 description 10
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 10
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 235000013616 tea Nutrition 0.000 description 9
- 108010010234 HDL Lipoproteins Proteins 0.000 description 8
- 102000015779 HDL Lipoproteins Human genes 0.000 description 8
- 108010007622 LDL Lipoproteins Proteins 0.000 description 8
- 102000007330 LDL Lipoproteins Human genes 0.000 description 8
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 8
- 230000032683 aging Effects 0.000 description 8
- 230000003078 antioxidant effect Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 8
- 229940012843 omega-3 fatty acid Drugs 0.000 description 8
- 239000006187 pill Substances 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- 240000001548 Camellia japonica Species 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 235000018597 common camellia Nutrition 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 244000020518 Carthamus tinctorius Species 0.000 description 6
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000003712 anti-aging effect Effects 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 229940114079 arachidonic acid Drugs 0.000 description 5
- 235000021342 arachidonic acid Nutrition 0.000 description 5
- 210000001772 blood platelet Anatomy 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 244000068645 Carya illinoensis Species 0.000 description 4
- 235000009025 Carya illinoensis Nutrition 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000007443 Neurasthenia Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 206010003549 asthenia Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000007969 cellular immunity Effects 0.000 description 3
- 201000001883 cholelithiasis Diseases 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 229940118019 malondialdehyde Drugs 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000893976 Nannizzia gypsea Species 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- GPLOTACQBREROW-UHFFFAOYSA-N Phlegmanol A-acetat Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(=CC1=2)C=C(O)C(=O)C1=C(O)C(O)=CC=2C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 GPLOTACQBREROW-UHFFFAOYSA-N 0.000 description 2
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- KMJPKUVSXFVQGZ-UHFFFAOYSA-N TF2B Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 KMJPKUVSXFVQGZ-UHFFFAOYSA-N 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 235000020279 black tea Nutrition 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- LRFDUPNLCDXZOE-UHFFFAOYSA-N camellianin b Chemical compound OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(OC=2C=3C(=O)C=C(OC=3C=C(O)C=2)C=2C=CC(O)=CC=2)OC1CO LRFDUPNLCDXZOE-UHFFFAOYSA-N 0.000 description 2
- 235000012682 canthaxanthin Nutrition 0.000 description 2
- 239000001659 canthaxanthin Substances 0.000 description 2
- 229940008033 canthaxanthin Drugs 0.000 description 2
- 230000003177 cardiotonic effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 235000019416 cholic acid Nutrition 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- 201000010251 cutis laxa Diseases 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000004332 deodorization Methods 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- -1 diene prostaglandin Chemical class 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 239000008157 edible vegetable oil Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 206010016766 flatulence Diseases 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 208000001130 gallstones Diseases 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000005550 inflammation mediator Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000006014 omega-3 oil Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- NDVASEGYNIMXJL-UHFFFAOYSA-N sabinene Chemical compound C=C1CCC2(C(C)C)C1C2 NDVASEGYNIMXJL-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 2
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- NDVASEGYNIMXJL-NXEZZACHSA-N (+)-sabinene Natural products C=C1CC[C@@]2(C(C)C)[C@@H]1C2 NDVASEGYNIMXJL-NXEZZACHSA-N 0.000 description 1
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- 239000001169 1-methyl-4-propan-2-ylcyclohexa-1,4-diene Substances 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- ZEASWHWETFMWCV-UHFFFAOYSA-N 7-O-(2-O-Acetyl-6-O-Methyl-beta-D-glucuronoside)-4',5,7-Trihydroxyflavone Natural products C=1C(O)=C(O)C2=C(O)C(=O)C=C(C3C(CC4=C(O)C=C(O)C=C4O3)OC(=O)C=3C=C(O)C(O)=C(O)C=3)C=C2C=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 ZEASWHWETFMWCV-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 244000235603 Acacia catechu Species 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 206010056375 Bile duct obstruction Diseases 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 206010008803 Chromoblastomycosis Diseases 0.000 description 1
- 208000015116 Chromomycosis Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- DBPRUZCKPFOVDV-UHFFFAOYSA-N Clorprenaline hydrochloride Chemical compound O.Cl.CC(C)NCC(O)C1=CC=CC=C1Cl DBPRUZCKPFOVDV-UHFFFAOYSA-N 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- QRMPRVXWPCLVNI-UHFFFAOYSA-N Curcumenol Natural products C1C(=C)C2CCC(C)C22CC(C(C)C)C1(O)O2 QRMPRVXWPCLVNI-UHFFFAOYSA-N 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000003849 Cytochrome P450 Human genes 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 241000712469 Fowl plague virus Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 206010023424 Kidney infection Diseases 0.000 description 1
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 241001480037 Microsporum Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000192023 Sarcina Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- BVMDSEFJGKQBKJ-UHFFFAOYSA-N Theaflavin 3'-gallate Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC1=C(O)C=C(O)C2=C1OC(C=1C=C(O)C(O)=CC=1)=CC2=O BVMDSEFJGKQBKJ-UHFFFAOYSA-N 0.000 description 1
- ZEASWHWETFMWCV-ISBUVJFSSA-N Theaflavin 3,3'-digallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C2=CC(=CC(=O)C(O)=C2C(O)=C(O)C=1)[C@@H]1[C@@H](CC2=C(O)C=C(O)C=C2O1)OC(=O)C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 ZEASWHWETFMWCV-ISBUVJFSSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 241001480046 Trichophyton schoenleinii Species 0.000 description 1
- 241000223230 Trichosporon Species 0.000 description 1
- FZPYMZUVXJUAQA-ZDUSSCGKSA-N Turmerone Chemical compound CC(C)=CC(=O)C[C@H](C)C1=CCC(C)=CC1 FZPYMZUVXJUAQA-ZDUSSCGKSA-N 0.000 description 1
- FZPYMZUVXJUAQA-UHFFFAOYSA-N Turmerone Natural products CC(C)=CC(=O)CC(C)C1=CCC(C)=CC1 FZPYMZUVXJUAQA-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 244000089698 Zanthoxylum simulans Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 150000001361 allenes Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- FAMPSKZZVDUYOS-UHFFFAOYSA-N alpha-Caryophyllene Natural products CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 description 1
- KQAZVFVOEIRWHN-UHFFFAOYSA-N alpha-thujene Natural products CC1=CCC2(C(C)C)C1C2 KQAZVFVOEIRWHN-UHFFFAOYSA-N 0.000 description 1
- XOCANRBEOZQNAQ-KBPBESRZSA-N alpha-turmerone Natural products O=C(/C=C(\C)/C)C[C@H](C)[C@H]1C=CC(C)=CC1 XOCANRBEOZQNAQ-KBPBESRZSA-N 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000005189 cardiac health Effects 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 229940117948 caryophyllene Drugs 0.000 description 1
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- ISFMXVMWEWLJGJ-NZBPQXDJSA-N curcumenol Chemical compound CC1=C[C@](O2)(O)C(=C(C)C)C[C@@]22[C@@H](C)CC[C@H]21 ISFMXVMWEWLJGJ-NZBPQXDJSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 1
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 150000002206 flavan-3-ols Chemical class 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003660 hair regeneration Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000009390 immune abnormality Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 244000000053 intestinal parasite Species 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000008965 mitochondrial swelling Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000002433 mononuclear leukocyte Anatomy 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 235000021485 packed food Nutrition 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000007875 phellandrene derivatives Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 208000024466 platelet membrane fluidity Diseases 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229930006696 sabinene Natural products 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- IKLDTEFDTLKDRK-UHFFFAOYSA-N theaflavin 3'-gallate Natural products OC1Cc2c(O)cc(O)cc2OC1c3cc4C=C(C=C(O)C(=O)c4c(O)c3O)C5Oc6cc(O)cc(O)c6CC5OC(=O)c7cc(O)c(O)c(O)c7 IKLDTEFDTLKDRK-UHFFFAOYSA-N 0.000 description 1
- DZGQZNRJDFZFLV-UHFFFAOYSA-N theaflavin 3,3'-digallate Natural products OC1=CC(=Cc2cc(C3Oc4cc(O)cc(O)c4CC3OC(=O)c5cc(O)c(O)c(O)c5)c(O)c(O)c2C1=O)C6Oc7cc(O)cc(O)c7CC6OC(=O)c8cc(O)c(O)c(O)c8 DZGQZNRJDFZFLV-UHFFFAOYSA-N 0.000 description 1
- AATSUYYYTHJRJO-UHFFFAOYSA-N theaflavin 3-gallate Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(=CC(=O)C(O)=C1C(O)=C2O)C=C1C=C2C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 AATSUYYYTHJRJO-UHFFFAOYSA-N 0.000 description 1
- 235000002365 theaflavin-3'-gallate Nutrition 0.000 description 1
- 235000008230 theaflavin-3,3'-digallate Nutrition 0.000 description 1
- 235000007900 theaflavin-3-gallate Nutrition 0.000 description 1
- AATSUYYYTHJRJO-RZYARBFNSA-N theaflavin-3-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=C(O)C(O)=C2C(=O)C(O)=CC(=CC2=C1)[C@H]1OC2=CC(O)=CC(O)=C2C[C@H]1O)C(=O)C1=CC(O)=C(O)C(O)=C1 AATSUYYYTHJRJO-RZYARBFNSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/40—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the fats used
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/50—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by shape, structure or physical form, e.g. products with supported structure
- A23G3/54—Composite products, e.g. layered, coated, filled
- A23G3/545—Composite products, e.g. layered, coated, filled hollow products, e.g. with inedible or edible filling, fixed or movable within the cavity
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a composite gel candy and a preparation method thereof. The beneficial effects are as follows: the process has reasonable design, convenient operation, low process cost, good flatness of the capsule skin of the product, good taste and color and is suitable for industrial production; the product is accurately absorbed through the enteric-coated intestinal tract, and is mainly used for regulating immunity, preventing cardiovascular and cerebrovascular diseases, clearing lung, conditioning respiratory system, strengthening brain, improving intelligence, improving microcirculation, clearing intestine, removing toxic substances, moistening intestinal tract, inhibiting bacteria, diminishing inflammation and resisting viruses. Regulating chronic epidemic diseases such as hypertension, diabetes, gout and the like, influenza virus and the like; the product obtained by the preparation method of the composite gel candy has the tea polyphenol content of more than 20 percent, the linoleic acid content of more than 4.5 percent, the theaflavin content of more than 1.0 percent and the alpha-linolenic acid content of more than 4 percent, and has a health-care function.
Description
Technical Field
The invention belongs to the technical field of candy preparation, relates to a process of gel candy, and particularly relates to a composite gel candy and a preparation method thereof.
Background
The variety of the candy is more, and the combination of some functional components and the candy needs special process for assistance. The traditional functional candies are mostly based on gel, and functional components are wrapped by different core materials and capsule shells, so that the functional components can be protected, and the candies have the sweet taste of the candies. However, the capsule skin suitable for different core materials is different, and the capsule skin not only needs to have a wrapping effect, but also needs to be capable of protecting the functional components of the core materials from being damaged. For industrial production, lower production cost needs to be selected, and the appearance and the mouthfeel of the product are more consistent with those of the public.
In view of this, this patent is filed.
Disclosure of Invention
In order to overcome the defects of the prior art, the process has reasonable design, convenient operation, low process cost, good flatness of the capsule shell of the product, good taste and color and is suitable for industrial production; the product obtained by the preparation method of the composite gel candy has good capsule skin flatness and good color and taste, and the finished product has the tea polyphenol content of more than 20 percent, the linoleic acid content of more than 4.5 percent, the theaflavin content of more than 1.0 percent and the alpha-linolenic acid content of more than 4 percent, thereby having the health-care function.
The invention aims to provide a composite gel candy and a preparation method thereof.
The composite gel candy according to the specific embodiment of the invention is prepared by mixing the following components in percentage by mass: 250-300 parts of gelatin, 120-130 parts of glycerol, 250-300 parts of purified water, 10-20 parts of maltitol, 50-100 parts of camellia oil, 10-50 parts of pecan oil, 10-50 parts of theaflavin, 100-150 parts of catechin, 5-10 parts of rosemary oil, 20-50 parts of safflower seed oil, 1-10 parts of zanthoxylum oil, 20-50 parts of linseed oil, 5-10 parts of ginger oil and 10-20 parts of beeswax.
The composite gel candy according to the embodiment of the invention is prepared by mixing the following components in percentage by mass: 270-380 parts of gelatin, 122-128 parts of glycerol, 270-280 parts of purified water, 12-18 parts of maltitol, 70-80 parts of camellia oil, 20-40 parts of pecan oil, 30-40 parts of theaflavin, 120-140 parts of catechin, 6-8 parts of rosemary oil, 30-40 parts of safflower seed oil, 3-8 parts of zanthoxylum oil, 30-40 parts of linseed oil, 6-8 parts of ginger oil and 12-18 parts of beeswax.
The composite gel candy according to the embodiment of the invention is prepared by mixing the following components in percentage by mass: 275 parts of gelatin, 125 parts of glycerol, 275 parts of purified water, 15 parts of maltitol, 75 parts of camellia oil, 35 parts of pecan oil, 35 parts of theaflavin, 130 parts of catechin, 7 parts of rosemary oil, 35 parts of safflower seed oil, 5 parts of zanthoxylum oil, 35 parts of linseed oil, 7 parts of ginger oil and 15 parts of beeswax.
A composite gel confection according to an embodiment of the present invention, wherein the theaflavins are of 40% purity.
A composite gel candy according to an embodiment of the present invention, wherein the purity of the catechin is 80%.
According to the specific embodiment of the invention, the preparation method of the composite gel candy comprises the following steps:
(1) pretreatment of raw materials: uniformly mixing theaflavin and catechin, and sieving with 100 mesh sieve to obtain powder for later use; uniformly mixing the pecan oil, the rosemary oil, the zanthoxylum oil, the safflower seed oil and the ginger oil to obtain standby mixed oil;
(2) preparing gel liquid: adding one third to one half of purified water into maltitol to dissolve for later use, mixing glycerol and the rest of purified water, heating, boiling and stirring the dissolved maltose, adding gelatin when the temperature is 70 ℃, continuously heating to 75 ℃, keeping the temperature and stirring for about 1 hour, vacuumizing to 0.06-0.08 Mpa to remove bubbles, vacuumizing for about 30 minutes, then discharging air, standing for 4-6 hours to prepare gel liquid, and keeping the temperature at 50-60 ℃ for later use;
(3) preparing capsule core feed liquid: heating linseed oil to 75 ℃, starting a stirring paddle, adding beeswax, continuing stirring for 5 minutes after the beeswax is completely dissolved, adding camellia oil, cooling to about 45 ℃, mixing with the standby mixed oil prepared in the step (1), stirring for 15 minutes, mixing with the standby powder prepared in the step (1), stirring for 25 minutes, vacuumizing to-0.06-0.08 MPa, and removing bubbles to obtain capsule core feed liquid for standby;
(4) and (3) pressing and forming: conveying the gel liquid prepared in the step (2) and the capsule core liquid prepared in the step (3) to a pelleting press under the conditions that the temperature is 18-24 ℃ and the humidity is 30-40%, conveying candies extruded by the pelleting press to a rolling cage by using a conveying belt according to process parameters () of the pelleting press, and shaping for 1h to obtain extruded candies;
(5) and (3) drying: and (4) carrying out ventilation drying on the pressed candy obtained in the step (4) for more than 10 hours to obtain the composite gel candy.
According to the specific embodiment of the invention, the preparation method of the composite gel candy comprises the following steps:
(1) pretreatment of raw materials: uniformly mixing theaflavin and catechin, and sieving with 100 mesh sieve to obtain powder for later use; uniformly mixing the pecan oil, the rosemary oil, the zanthoxylum oil, the safflower seed oil and the ginger oil to obtain standby mixed oil;
(2) preparing gel liquid: dissolving maltitol in purified water of two fifths for use, mixing glycerol with the rest purified water, heating, decocting and stirring the dissolved maltose, adding gelatin at 70 deg.C, heating to 75 deg.C, stirring for 1 hr, vacuumizing to-0.07 Mpa to remove bubbles, vacuumizing for 30 min, discharging gas, standing for 5 hr to obtain gel solution, and keeping at 55 deg.C;
(3) preparing capsule core feed liquid: heating linseed oil to 75 ℃, starting a stirring paddle, adding beeswax, continuing stirring for 5 minutes after the beeswax is completely dissolved, adding camellia oil, cooling to about 45 ℃, mixing with the standby mixed oil prepared in the step (1), stirring for 15 minutes, mixing with the standby powder prepared in the step (1), stirring for 25 minutes, vacuumizing to-0.07 MPa, and removing bubbles to obtain capsule core feed liquid for standby;
(4) and (3) pressing and forming: conveying the gel liquid prepared in the step (2) and the capsule core liquid prepared in the step (3) to a pelleting press under the conditions of temperature of 20 ℃ and humidity of 35%, conveying the candies extruded by the pelleting press to a rolling cage by using a conveying belt according to process parameters () of the pelleting press, and shaping for 1h to obtain pressed candies;
(5) and (3) drying: and (4) carrying out ventilation drying on the pressed candy obtained in the step (4) for more than 10 hours to obtain the composite gel candy.
According to the method for preparing the composite gel candy, the gel liquid is filtered by 80 meshes after the air is discharged in the step (2).
According to the method for preparing the composite gel candy, before the step (4) is carried out, a pill pressing machine is debugged, the mould is poured, the core material is injected, the difference of pills is measured to be 1 +/-7.5%, the thickness of two sides of the appearance rubber is checked to be consistent, the interface is firm, and the checking is carried out once every 60 min.
According to the method for preparing the above composite gel candy according to the embodiment of the present invention, the gum candy is slightly turned 1 time every 2 hours during the drying process of the step (5).
The raw materials of the formula have the following effects and effects:
firstly, the main effects of safflower camellia oil are as follows: the camellia trees with safflower are rare, only 1% of camellia trees can have safflower, and the camellia trees can only grow in alpine regions with the altitude of more than 800m, and the camellia trees are picked from the camellia trees grown in original ecological clean valleys with surrounding mountains, cloud and fog, large temperature difference between day and night and no pollution to air.
The excellent characteristics of the safflower camellia oil make the safflower camellia oil become superior products in edible oil and fat, and the characteristics are due to the inherent nutritional constitution of the camellia oil. The research of modern medicine and food science shows that the camellia oil is rich in multiple components which are most easy to be in human health, including fatty acid (unsaturated fatty acid accounts for more than 90%), camellin, tea polyphenol, saponin, tannin, antioxidant, squalene with anti-inflammatory effect and flavonoid substance.
The camellia oil is also rich in vitamins, amino acids and various mineral substances, particularly zinc element which is praised as 'flowers of life' by medical scientists and nutriologists, and meanwhile, the camellia oil does not contain erucic acid (easily caused by rancidity), cholesterol, aflatoxin and any other undesirable substances.
The safflower camellia oil has the functions of reducing blood fat and blood sugar, promoting digestion, strengthening bones, resisting aging and the like, and contains 80% of unsaturated fatty acid, vitamin E, flavonoids, canthaxanthin and antioxidant substances.
Meanwhile, the medicine has the following effects:
1. and (3) reducing blood fat: contains a large amount of unsaturated fatty acids, can combine with cholesterol in blood to form high density lipoprotein, and can reduce triglyceride and cholesterol in blood;
2. and (3) reducing blood sugar: contains specific bioactive substances: the tea polyphenol and the camellia glycerol can effectively reduce fasting blood glucose and help to improve lipid metabolism of diabetics;
3. improving the digestive function: can effectively improve the functions of the stomach, the spleen, the liver and the gallbladder, prevent gallstones, improve gastritis and duodenal ulcer and effectively improve the functions of the digestive system of the body;
4. anti-aging: the vitamin E containing the antioxidant can reduce free radicals of a body, protect the body function and delay aging, and the canthaxanthin brass substances can play a role in enhancing the immunity of the body and effectively resisting aging;
5. strengthening bones: can help promote the growth of bones, the generation of body mineral substances and the absorption of calcium, and effectively prevent and treat osteoporosis;
6. preventing cardiovascular and cerebrovascular diseases: the health-care food is rich in unsaturated fatty acid, is beneficial to heart health and antioxidant substances, and can effectively prevent cardiovascular epidemic diseases;
7. and (3) beautifying and protecting skin: the unsaturated fatty acid contained in the product can moisten skin, eliminate wrinkles and relieve dry skin, and the product is rich in vitamin E, and can improve skin pruritus, eliminate pouch and dark eye, and improve skin resistance to ultraviolet;
8. auxiliary weight loss: rich in unsaturated fatty acid, can be rapidly absorbed by body, and can not transform fat to accumulate in body to cause obesity.
Secondly, the pecan oil has the main effects: the high-quality variety of the pecan which is researched and developed by China by self is adopted, and the novel pecan kernels with organic quality are cultivated and planted by an organic method, and the pecan kernels are refined by a scientific cold pressing mode without any addition and the quality of crude oil is guaranteed. It has effects in invigorating spleen and replenishing qi, tonifying kidney, nourishing brain, moistening skin, and blackening hair and beard. It is rich in protein, amino acids, vitamins, essential oil acids, linoleic acid, trace elements, etc.
Meanwhile, the medicine has the following effects:
1. preventing cardiovascular and cerebrovascular diseases: the contained essential oleic acid, linoleic acid and antioxidant substances can effectively prevent coronary heart disease, stroke, senile dementia and the like;
2. brain strengthening and intelligence improving: the rich trace elements of zinc and manganese are important components of the pituitary, which is beneficial to the nutrition supplement of the brain;
3. beautifying and anti-aging: the contained vitamin E can prevent cells from being oxidized by free radicals, damage anti-aging substances, and has the effects of delaying aging, maintaining beauty, keeping young and blackening hair and beard;
4. preventing neurasthenia: can act as a neurasthenia agent. Can be used for preventing dizziness, insomnia, palpitation, amnesia, and general weakness;
5. sterilization and inflammation diminishing: has antibacterial, antiinflammatory, antiviral, astringent, and antipruritic effects;
6. treating cholelithiasis: the rich cupronic acid can prevent the binding of mucin and calcium ion non-binding bilirubin and can dissolve and eliminate mucin and excrete mucin for long-term consumption to avoid operation.
Thirdly, the safflower seed oil has the main effects: the safflower seed oil contains linseed oil and linolenic acid as main components, is the oil with the highest linolenic acid content in food, and has high contents of protein, mineral vitamin E and unsaturated fatty acid and high nutritive value.
Meanwhile, the composition contains the following components and effects:
1. linoleic acid: is a component of cells, and particularly participates in the synthesis of mitochondria and cell membrane phosphorus. Linoleic acid deficiency may lead to mitochondrial swelling, altered cell membrane mechanisms, altered functions, increased membrane permeability, and increased fragility. Linoleic acid is closely related to lipid metabolism. Cholesterol in the body is bound to fatty acids before it is transported in the body for normal metabolism. In the absence of linoleic acid, cholesterol transport is hindered from normal metabolism and can be deposited in the body, ultimately leading to disease. Linoleic acid is a necessary prerequisite for the synthesis of prostaglandins, and the tissue's ability to form prostaglandins is diminished due to the lack of linoleic acid in the body. Linoleic acid also has a protective effect on some skin damages caused by X-rays. The safflower seed oil not only can prevent cardiovascular and cerebrovascular diseases, but also has peculiar efficacy of treating fatty liver. Another effect of linoleic acid is the raw material that makes up the cell membrane. The material constituting the cell membrane is an unsaturated fatty acid. Linoleic acid has the functions of strengthening metabolism and enhancing cell activity;
2. vitamin E: safflower seed oil is rich in natural vitamin E, the average content of the safflower seed oil is about 800mgDL, and the safflower seed oil is the highest content in all plants, so the safflower seed oil is known as the crown of vitamin E. The vitamin E in the safflower seed oil is pure natural vitamin E with life activity. Vitamin E is a very strong reducing agent and has a very strong anti-oxidation effect. It also has antiaging effect, and can revive aged and aged cells and tissues. Vitamin E is a compound that can improve human immunity.
Fourthly, the main effects of the zanthoxylum oil are as follows: pungent and warm in flavor, entering spleen and stomach meridians; has the effects of invigorating stomach, warming spleen and stomach for dispelling cold, eliminating dampness and relieving pain, killing parasites and detoxifying, relieving itching and removing fishy smell; it is mainly used for treating emesis, arthralgia due to wind-cold-dampness, and toothache. According to the record of Li Shizhen Ben Cao gang mu: chinese prickly ash has the functions of strengthening teeth, blackening hair, improving eyesight, being taken for a long time, having good color, resisting aging, prolonging life and strengthening spirit. "
Pungent flavor and warm property. It has effects in stimulating appetite, warming middle warmer, relieving pain, and expelling intestinal parasites.
Can be used for treating deficiency-cold of spleen and stomach, anorexia, abdominal psychroalgia, emesis, and diarrhea; abdominal pain due to roundworms.
Five, the main effects of the rosemary oil are as follows: has the effects of prolonging shelf life, astringing, regulating greasy and dirty skin, promoting blood circulation, and stimulating hair regeneration; relieving skin congestion, edema, and swelling; astringe skin, improve dandruff; relieving menstrual pain, promoting urination, and reducing weight; has effects in improving gastrointestinal function, heart function, lung function, liver function, and gallbladder function; cardiotonic, lowering blood pressure, and regulating anemia; refreshing, restoring central nerve activity; the skin is firmer and more elastic for the convergence of the skin after losing weight.
Meanwhile, the medicine has the following effects:
1. the skin curative effect is that the rosemary oil has strong contraction effect, contracts loose skin and can relieve congestion and swelling; can improve dandruff and stimulate hair growth;
2. the psychological curative effect activates brain cells, makes the brain clear and enhances the memory; improving nervous mood, depression and lethargy; can invigorate vitality, strengthen soul, and has functions of vibration and excitation;
3. the physiological curative effect is as follows: rosemary is a cardiotonic and cardiac stimulant, so that hypotension is recovered to be normal, and the effect of conditioning anemia is also good; it also helps lung, and can improve common cold, asthma, chronic bronchitis and influenza; reducing hepatitis and liver cirrhosis, as well as gallstones, jaundice, bile duct obstruction; improving digestion function, and relieving colitis, dyspepsia, flatulence and gastralgia. 4. The treatment effect is as follows: rosemary oil has remarkable effects on brain and central nervous system, and also has effects in eliminating miscarriage and promoting intelligence development. Has good stimulating effect on brain, and can enhance memory. It is useful for treating headache, migraine, neuralgia, mental fatigue and neurasthenia, and is especially suitable for treating intestinal infection and dysentery, relieving dyspepsia and flatulence, coordinating symptoms of liver discomfort and jaundice, and relieving pain caused by arthritis, rheumatism and gout. It also helps to treat arteriosclerosis, palpitations, poor circulation and varicose veins. The effect of rosemary oil in promoting diuresis is beneficial to reducing the water holding amount in menstrual period, and is also beneficial to decomposing fat and reducing weight. For the respiratory system it has a therapeutic effect on cough from asthma, bronchitis, mucositis sinusitis and the segment. It has astringent effect and is effective for treating loose skin. Its stimulating action is beneficial to regulating scalp dysfunction and promoting hair growth;
sixthly, introduction effects of theaflavin: theaflavin is a substance which is dissolved in ethyl acetate and is orange yellow in black tea, is prepared by oxidizing and condensing polyphenols and derivatives thereof, the content of the theaflavin in the black tea is generally 0.3-1.5%, and the theaflavin has various potential functions related to human health, such as antioxidation, cardiovascular disease prevention and treatment, blood fat reduction, cancer prevention and the like.
Theaflavin is composed of polyphenols, amino acids, vitamin C, vitamin E, provitamin A, flavone and flavonol. Theaflavin is the main component of theaflavin and has 12 components in total, wherein theaflavin, theaflavin-3-gallate, theaflavin-3, 3 '-digallate and theaflavin-3' -gallate are the 4 most main theaflavins. The tea is mainly prepared by the paired oxidation and condensation of simple catechin and gallocatechin in the tea processing.
Meanwhile, the medicine has the following effects:
1. cancer prevention and resistance: the tea has cancer preventing and resisting effects, the main effective components are tea polyphenol, catechin monomer and tea pigment, theaflavin has the functions of resisting mutation, inhibiting the activity of cytochrome P450, inhibiting extracellular signals and proliferation of cancer cells, resisting inflammation, preventing cancer chemoprevention and the like, and theaflavin has the advantages of oxidation resistance and good medical health-care functions, such as prevention of cardiovascular and cerebrovascular diseases, prevention of decayed teeth, cancer prevention and resistance, antibiosis and antivirus and the like. The theaflavin monomer has good inhibition effect on human fibrosarcoma, macrophage, mouse lung cell and the like, and has obvious inhibition effect on gastric cancer cell strains, liver cancer cell strains and acute promyelocytic leukemia cell strains;
2. antioxidation: theaflavin has antioxidant effect by regulating in vivo biological enzyme system activity, directly eliminating free radical, complexing with metal ion, and preventing oxidation of low density lipoprotein. Glutathione S transferase GST can catalyze the combination reaction of nucleophilic glutathione and various electrophilic exogenous compounds, and has detoxification effect;
3. anti-inflammatory: inflammation is caused by the mediation of inflammation mediators, wherein the main inflammation mediators are prostaglandin, cytokines, growth factors, bacterial endotoxin and the like to induce the synthesis of inflammatory cells, theaflavin can reduce the generation of endogenous uric acid and reduce the attack of gouty arthritis, and is superior to probenecid and allopurinol in certain aspects;
4. and (3) antivirus: theaflavin can inhibit infection of kidney MDCK cells by influenza A virus and influenza B virus by inhibiting virus adsorption on cells. In addition, it has effects in inhibiting infection of rotavirus and enterovirus by cell line;
5. anti-cardiovascular diseases: theaflavin is a relatively new research field at present for resisting cardiovascular diseases. The mechanism is based on hemorheology. Basic research and clinical tests show that the injection has the effects of obviously resisting coagulation, promoting fibrinolysis and preventing platelet adhesion and aggregation, can obviously reduce triglyceride in the serum of high-fat animals, has the mechanism of improving erythrocyte deformability, adjusting erythrocyte aggregation and platelet adhesion aggregation, reducing plasma viscosity, improving microcirculation, ensuring the supply of tissue blood and oxygen, improving the overall immunity and tissue metabolism level of an organism, achieves the purposes of preventing and treating diseases, can obviously reduce triglyceride and low-density lipoprotein LDL in the serum of high-fat animals, and improves high-density lipoprotein HDL. TFs have obvious inhibitory effect on angiotensin I converting enzyme and good effect of reducing blood;
6. and (3) deodorization: the odor has various types, mainly comprises methyl mercaptan, ammonia gas, hydrogen sulfide, toluene and other compounds, and has the mechanism action that the catechin has a strong antibacterial effect and can inhibit the growth and the reproduction of microorganisms in the oral cavity, so that the generation of the methyl mercaptan is reduced, and the theaflavin has the effect of directly removing the methyl mercaptan.
Seventh, introduction of catechin effects: catechin, named as catechin, tea tannin, etc., is a derivative of flavanol, and has a molecular formula of C15H14O6It is extracted from catechu, and is colorless crystalline solid, which can be dissolved in water, and its aqueous solution can be easily polymerized into amorphous tannin by heating or in the presence of inorganic acid.
The efficacy and effect of catechin:
1. scavenging free radicals: catechin is natural oil antioxidant, has antioxidant activity even higher than that of vitamin E, and can scavenge free radicals generated by human body to protect cell membrane;
2. and (3) aging delaying: catechin acts on free radicals, so that aging can be delayed;
3. preventing tooth decay: catechins can significantly reduce dental plaque and alleviate periodontal disease. The tooth has stronger resistance to acid erosion;
4. the intestine clearing effect is as follows: the catechin can inhibit pathogenic bacteria (such as botulinum) of human body, and does not harm the multiplication of beneficial bacteria (such as lactic acid bacteria), so that the product has intestinal function;
5. the antibacterial effect is as follows: the catechin can inhibit germs causing human skin diseases and has good curative effect on eczema treatment;
6. the deodorization effect is as follows: catechin can remove odor of methyl mercaptan, so as to remove halitosis of smoker, and resist bacteria producing odor in intestinal tract;
7. other effects catechin also has effects of inhibiting blood pressure (lowering diastolic and systolic pressure) and blood sugar (inhibiting glycolytic enzyme), lowering cholesterol and Low Density Lipoprotein (LDL) in blood, increasing the amount of High Density Lipoprotein (HDL) (used as low cholesterol egg in Japan), resisting radiation and ultraviolet rays (made into cosmetics for preventing ultraviolet rays in the United states), resisting mutation (proven in microorganisms, but no report of human body test).
Eighthly, linseed oil: is the highest in linolenic acid and linoleic acid content, the linolenic acid is a fatty acid, which can cause the resistance to be reduced when a human body lacks the linolenic acid, can improve the intelligence and promote the brain development, and is a good tonic for the old and children. In addition, it can also enhance the absorption of various nutrient elements. Has good blood pressure lowering and blood fat reducing effects for patients with hypertension and hyperlipemia.
Meanwhile, the medicine has the following effects:
1. preventing cardiovascular and cerebrovascular diseases: due to thrombosis, the blood vessels become blocked and the tissue cells are not supplied with oxygen and nutrients, eventually leading to death. Thrombosis is easily formed at coronary artery and cerebral vessels of heart, and myocardial infarction and cerebral infarction are caused. It is known that an important factor contributing to thrombus formation is the process of platelet aggregation. Alpha-linolenic acid can alter platelet membrane fluidity, thereby altering platelet responsiveness to stimuli and the number of platelet surface receptors. Therefore, the formation of thrombus can be effectively prevented;
2. and (3) reducing blood fat: the metabolite of alpha-linolenic acid has mild regulation effect on blood lipid metabolism, can promote the conversion of plasma low-density lipoprotein (LDL) to high-density lipoprotein (HDL), and enables the low-density lipoprotein (LDL) to be reduced and the high-density lipoprotein (HDL) to be increased, thereby achieving the purposes of reducing blood lipid and preventing atherosclerosis;
3. reduction of borderline hypertension: the blood pressure is 145/90mmHg to 160/95mmHg, which is called critical hypertension and is initial hypertension. If the hypotensor is used for a long time, many adverse reactions are easy to cause. The metabolite of the alpha-linolenic acid can expand blood vessels and enhance the elasticity of the blood vessels, thereby playing a role in reducing blood pressure;
4. inhibiting the development and metastasis of cancer: normal body cells can generate pathological changes due to the imbalance of body functions, and cancer cells can generate a large amount of diene prostaglandin which can inhibit the functions of various immune cells after being formed, so that the functions of the immune system of a human body are reduced, and the cancer cells can proliferate and metastasize. The metabolic product of alpha-linolenic acid can directly reduce the generation amount of carcinogenic cells, weaken the agglutination of blood platelets, inhibit the generation of diene prostaglandin, and recover and improve the functions of the immune system of a human body. Thereby effectively preventing the formation of cancer and inhibiting the metastasis thereof. The incidence of Eszky human breast cancer is very low because they eat a large amount of fish or other marine products, and although the fat intake is large, the unsaturated fatty acids are abundant, mainly n-3 series fatty acids (alpha-linolenic acid), so the incidence of cancer is very low;
5. the alpha-linolenic acid can reduce the content of Arachidonic Acid (AA) in the mononuclear leukocyte (RMNS) and the phospholipid of a mast cell membrane, reduce the release amount of AA during the allergic reaction, and further reduce the generation of LT4 (leukotriene); the metabolite EPA also competes with AA;
6. action of desaturases: alpha-linolenic acid has inhibitory effect on PAF (platelet aggregation activating factor) which is an intermediate of anaphylaxis. Therefore, alpha-linolenic acid is considered to have an inhibitory effect on allergic reactions and inflammations. Clinical studies have shown that the pathogenesis of psoriasis is mainly due to a disturbance of arachidonic acid metabolism, while the symptoms are reduced after a certain intake of EPA. A large number of animal experiments prove that the hypersensitive reaction of the physique is caused by the lack of food containing alpha-linolenic acid;
7. and (3) aging inhibition: with the increase of age, the number of various free radicals in the body is increased, and the quantity of glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) is gradually reduced, and the activity is gradually weakened, so that the generation of a free radical metabolite Malondialdehyde (MDA) is increased, cells are damaged, and the functions of tissues and organs are reduced. After the alpha-linolenic acid is taken, GSH-Px and SOD activity are increased, MDA generation is reduced, and the anti-aging effect of the alpha-linolenic acid is revealed.
Omega 3 is a general name of linolenic acid, is an essential fatty acid for human bodies, and has good effects on regulating immunity and eliminating internal inflammation.
Omega 3 is a nutrient from food, which can not kill virus directly, but can resist virus by enhancing organism immunity and inhibiting inflammation overreaction.
Scientific research shows that omega 3 fatty acid can obviously enhance the nonspecific immune system of the body, namely the resistance is increased. Chicks and layers fed with sufficient omega 3 diet are more resistant to attacks by fowl plague viruses (including newcastle disease virus and avian influenza virus). A 3-year study in germany shows that the number of colds or fevers per year for the elderly whose diet is fortified with omega 3 fatty acid nutrients is significantly lower than that of the control group.
Anti-inflammatory and anti-allergic, and avoids the stimulation of the immune system, and the effect is reflected on two aspects of cellular immunity and humoral immunity. In the aspect of cellular immunity, research shows that omega 3 fatty acid can inhibit the proliferation of human peripheral blood lymphocytes under the stimulation of mitogen, obviously inhibit IL-2 secretion of T cells, and further reduce the contrastive cellular immunity intensity.
In the aspect of humoral immunity, experiments show that omega 3 fatty acid can inhibit the production of cytokines including IL-1, TNF, IL-2 and other cytokines, and further regulate the intensity of the contrastive humoral immune response. Omega 3 fatty acids can modulate the intensity of such immune responses and reduce the damage to the body from the immune system.
Therefore, an enhanced omega 3 nutrient supply in the diet may reduce the severity of the pneumonia condition.
Omega 3 fatty acid, which is a brain-strengthening and intelligence-improving agent for your immune army, reduces the occurrence of diseases. At the same time, omega 3 fatty acids also accelerate the "battlefield" clean up, causing the body's inflammation to subside more rapidly. The immunity is related to factors such as nutrition, genes, trace elements, spirit, external antigens and the like. Typically, if immune cells lack nutrients and are not properly trained, they become hypoimmunity or immune abnormality (allergy). Many inflammatory diseases are not caused by a delayed action of the immune system, but rather by the immune military being a brute force without establishing a "smart" immune system. Under the condition, omega 3 fatty acid can be used for strengthening the brain and developing intelligence of an immune system and telling an immune army to slow down the supplement speed of white blood cells, so that the resolution process of inflammation is accelerated, the consumption number of the white blood cells in an infected area is reduced, excessive autoimmune reaction is relieved or avoided, and the immune army is prevented from having self-killing accidents.
Meanwhile, the process of eliminating inflammation is the process of clearing up the battlefield, and toxin and debris released in the fighting process are cleared up, so that the body cannot be affected badly. Resolvin (resolvin) produced by omega 3 accelerates the resolution of the inflammation, i.e. the recovery of the body. Omega 3 is commonly found in certain deep sea fish and plant seeds. A large number of research results show that the linseed oil is high-quality edible oil, is rich in omega 3 unsaturated fatty acid, and is economic and practical 'deep sea fish oil'. Omega 3 supplementation is a pathway from fat balance to nutritional balance and further to the balance of the immune system of the body. Only when the immune system of the human body is improved, the human body cannot be passively accepted in the presence of diseases, and the initiative of health can be really mastered in the hands of the human body.
Ninth, ginger oil: the ginger oil mainly contains turmerone, allene, borneol, a small amount of phellandrene, 1.8-cineole, sabinene, aryl-turmerone, curcumenol, caryophyllene and the like.
The ginger oil has the following effects:
1. the function of gallbladder promotion: the total amount of cholic acid and solid substances can be increased by oral administration, and researchers believe that the cholic acid and the solid substances are caused by the components a to camphor in the essential oil;
2. anti-inflammatory action: ginger oil can inhibit arthritis induced by Freund's adjuvant by oral administration. When the injection is injected into the abdominal cavity with 10mg/kg, the activity of the injection is equivalent to that of hydrocortisone with 5 mg/kg;
3. resisting pathogenic microorganisms and viruses: 5-100 g/ml of turmeric volatile oil can inhibit sarcina, Korotkoff, corynebacterium and prismatic spore bacteria, and has certain inhibitory effect on trichophyton rubrum, trichophyton gypseum, epidermophyton fusca, Microsporum gypseum, Microsporum lanosum, trichophyton schoenleinii, Candida albicans, cryptococcus neoformans, chromomycosis firmus, Trichosporon schenckii and the like;
in modern application, the ginger oil has special efficacy for external application to treat herpes zoster and herpes simplex. It is also useful for the treatment of general venereal disease infections.
The product is developed according to the formula concept of monarch, minister, assistant and guide in traditional Chinese medicine, is accurately absorbed through the enteric-coated intestinal tract, and is mainly used for regulating immunity, preventing cardiovascular and cerebrovascular diseases, clearing lung-heat, conditioning respiratory system, strengthening brain, improving intelligence, improving microcirculation, clearing intestine, expelling toxin, moistening intestinal tract, inhibiting bacteria, diminishing inflammation and resisting viruses. Regulating chronic epidemic diseases such as hypertension, diabetes, gout, and influenza virus.
Compared with the prior art, the invention has the following beneficial effects:
(1) the preparation method of the compound gel candy has the advantages of reasonable process design, convenient operation, low process cost, good flatness of the capsule skin of the product, good taste and color and luster, and suitability for industrial production; the product is developed according to the formula concept of monarch, minister, assistant and guide in traditional Chinese medicine, is accurately absorbed through the enteric-coated intestinal tract, and is mainly used for regulating immunity, preventing cardiovascular and cerebrovascular diseases, clearing lung-heat, conditioning respiratory system, strengthening brain, improving intelligence, improving microcirculation, clearing intestine, expelling toxin, moistening intestinal tract, inhibiting bacteria, diminishing inflammation and resisting viruses. Regulating chronic epidemic diseases such as hypertension, diabetes, gout and the like, influenza virus and the like;
(2) the product obtained by the preparation method of the composite gel candy has good capsule skin flatness and good color and taste, and the finished product has the tea polyphenol content of more than 20 percent, the linoleic acid content of more than 4.5 percent, the theaflavin content of more than 1.0 percent and the alpha-linolenic acid content of more than 4 percent, thereby having the health-care function.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the technical solutions of the present invention will be described in detail below. It is to be understood that the described embodiments are merely exemplary of the invention, and not restrictive of the full scope of the invention. All other embodiments, which can be derived by a person skilled in the art from the examples given herein without any inventive step, are within the scope of the present invention.
The camellia and the pecan used for preparing the camellia oil and the pecan oil are planted by self, the pecan oil and the camellia oil are prepared by cold pressing the raw materials, the cold pressing process is the prior art, and the detailed description is omitted. The other components are all commercial products.
A composite gel candy is prepared by mixing the following components in percentage by mass: 250-300 parts of gelatin, 120-130 parts of glycerol, 250-300 parts of purified water, 10-20 parts of maltitol, 50-100 parts of camellia oil, 10-50 parts of pecan oil, 10-50 parts of theaflavin, 100-150 parts of catechin, 5-10 parts of rosemary oil, 20-50 parts of safflower seed oil, 1-10 parts of zanthoxylum oil, 20-50 parts of linseed oil, 5-10 parts of ginger oil and 10-20 parts of beeswax.
Wherein the purity of theaflavin is 40%; the purity of catechin was 80%.
The preparation method of the composite gel candy comprises the following steps:
(1) pretreatment of raw materials: uniformly mixing theaflavin and catechin, and sieving with 100 mesh sieve to obtain powder for later use; uniformly mixing the pecan oil, the rosemary oil, the zanthoxylum oil, the safflower seed oil and the ginger oil to obtain standby mixed oil;
(2) preparing gel liquid: adding one third to one half of purified water into maltitol to dissolve for later use, mixing glycerol and the rest purified water, heating, boiling and stirring the dissolved maltose, adding gelatin when the temperature is 70 ℃, continuously heating to 75 ℃, keeping the temperature and stirring for about 1 hour, vacuumizing to 0.06-0.08 Mpa to remove bubbles, vacuumizing for about 30 minutes, then discharging air, filtering by 80 meshes, standing for 4-6 hours to prepare gel liquid, and keeping the temperature at 50-60 ℃ for later use;
(3) preparing capsule core feed liquid: heating linseed oil to 75 ℃, starting a stirring paddle, adding beeswax, continuing stirring for 5 minutes after the beeswax is completely dissolved, adding camellia oil, cooling to about 45 ℃, mixing with the standby mixed oil prepared in the step (1), stirring for 15 minutes, mixing with the standby powder prepared in the step (1), stirring for 25 minutes, vacuumizing to-0.06-0.08 MPa, and removing bubbles to obtain capsule core feed liquid for standby;
(4) and (3) pressing and forming: debugging a pelleting press, pouring a mold, injecting a core material, measuring the difference of pills to be in accordance with 1 +/-7.5%, checking that the thickness of two sides of an appearance rubber is consistent, the interface is firm, checking once every 60min, conveying the gel liquid prepared in the step (2) and the capsule core material liquid prepared in the step (3) to the pelleting press under the conditions of the temperature of 18-24 ℃ and the humidity of 30-40%, conveying candies extruded by the pelleting press to a rolling cage by using a conveying belt, and shaping for 1h to obtain pressed candies;
(5) and (3) drying: and (5) slightly turning the pressed candy obtained in the step (4) for 1 time every 2 hours, and carrying out ventilation drying for more than 10 hours to obtain the composite gel candy.
The obtained composite gel candy can be subjected to the following rechecking and packaging:
(6) and (4) lamp inspection: placing the dried candies on a light inspection machine, manually selecting out unqualified candies, and packaging qualified candies;
(7) inner packaging: packaging by adopting a packaging material meeting the food safety requirement, and sending out the packaged food to a clean area, wherein the steps (1) to (7) are operated in a 10 ten thousand-level clean area;
(8) and (3) outer packaging: boxing to obtain a finished product;
(9) and (6) inspection and warehousing: the finished product is respectively checked item by item according to each quality index specified by the product, and is put in storage after being checked to be qualified by a quality inspection department.
Example 1
The embodiment provides a composite gel candy which is prepared by mixing the following components in parts by mass: 250 parts of gelatin, 120 parts of glycerol, 250 parts of purified water, 10 parts of maltitol, 50 parts of camellia oil, 10 parts of pecan oil, 10 parts of theaflavin, 100 parts of catechin, 1 part of rosemary oil, 20 parts of safflower seed oil, 1 part of zanthoxylum oil, 20 parts of linseed oil, 1 part of ginger oil and 10 parts of beeswax.
Wherein the purity of theaflavin is 40%; the purity of catechin was 80%.
The preparation method of the composite gel candy comprises the following steps:
(1) pretreatment of raw materials: uniformly mixing theaflavin and catechin, and sieving with 100 mesh sieve to obtain powder for later use; uniformly mixing the pecan oil, the rosemary oil, the zanthoxylum oil, the safflower seed oil and the ginger oil to obtain standby mixed oil;
(2) preparing gel liquid: dissolving maltitol with one third of purified water for standby, mixing glycerol and the rest purified water, heating, decocting and stirring the dissolved maltose, adding gelatin when the temperature is 70 ℃, continuously heating to 75 ℃, keeping the temperature and stirring for about 1 hour, vacuumizing to 0.06Mpa to remove bubbles, vacuumizing for about 30 minutes, then discharging air, filtering by a 80-mesh sieve, standing for 4 hours to prepare gel liquid, and keeping the temperature at 50 ℃ for standby;
(3) preparing capsule core feed liquid: heating linseed oil to 75 ℃, starting a stirring paddle, adding beeswax, continuing stirring for 5 minutes after the beeswax is completely dissolved, adding camellia oil, cooling to about 45 ℃, mixing with the standby mixed oil prepared in the step (1), stirring for 15 minutes, mixing with the standby powder prepared in the step (1), stirring for 25 minutes, vacuumizing to-0.06 MPa, and removing bubbles to obtain capsule core feed liquid for standby;
(4) and (3) pressing and forming: debugging a pelleting press, wherein the mould pouring, the core material injection and the measured pill difference are in accordance with 1 +/-7.5%, checking that the thickness of two sides of an appearance rubber is consistent, the interface is firm, checking once every 60min, conveying the gel liquid prepared in the step (2) and the capsule core material liquid prepared in the step (3) to the pelleting press under the conditions of the temperature of 18 ℃ and the humidity of 30-40%, conveying the candies pressed by the pelleting press to a rolling cage by using a conveying belt, and setting for 1h to obtain pressed candies;
(5) and (3) drying: and (5) slightly turning the pressed candy obtained in the step (4) for 1 time every 2 hours, and carrying out ventilation drying for more than 10 hours to obtain the composite gel candy.
Example 2
The embodiment provides a composite gel candy which is prepared by mixing the following components in parts by mass: 300 parts of gelatin, 130 parts of glycerol, 300 parts of purified water, 20 parts of maltitol, 100 parts of camellia oil, 50 parts of pecan oil, 50 parts of theaflavin, 150 parts of catechin, 10 parts of rosemary oil, 50 parts of safflower seed oil, 10 parts of zanthoxylum oil, 50 parts of linseed oil, 10 parts of ginger oil and 20 parts of beeswax.
Wherein the purity of theaflavin is 40%; the purity of catechin was 80%.
The preparation method of the composite gel candy comprises the following steps:
(1) pretreatment of raw materials: uniformly mixing theaflavin and catechin, and sieving with 100 mesh sieve to obtain powder for later use; uniformly mixing the pecan oil, the rosemary oil, the zanthoxylum oil, the safflower seed oil and the ginger oil to obtain standby mixed oil;
(2) preparing gel liquid: dissolving maltitol in half of purified water for standby, mixing glycerol with the rest purified water, heating, decocting and stirring the dissolved maltose, adding gelatin when the temperature is 70 ℃, continuously heating to 75 ℃, keeping the temperature and stirring for about 1 hour, vacuumizing to 0.08Mpa to remove bubbles, vacuumizing for about 30 minutes, then discharging air, filtering by 80 meshes, standing for 6 hours to obtain gel liquid, and keeping the temperature at 60 ℃ for standby;
(3) preparing capsule core feed liquid: heating linseed oil to 75 ℃, starting a stirring paddle, adding beeswax, continuing stirring for 5 minutes after the beeswax is completely dissolved, adding camellia oil, cooling to about 45 ℃, mixing with the standby mixed oil prepared in the step (1), stirring for 15 minutes, mixing with the standby powder prepared in the step (1), stirring for 25 minutes, vacuumizing to-0.08 MPa, and removing bubbles to obtain capsule core feed liquid for standby;
(4) and (3) pressing and forming: debugging a pelleting press, pouring a mold, injecting a core material, measuring the difference of pills to be in accordance with 1 +/-7.5%, checking that the thickness of two sides of an appearance rubber is consistent, the interface is firm, checking once every 60min, conveying the gel liquid prepared in the step (2) and the capsule core material liquid prepared in the step (3) to the pelleting press under the conditions of 24 ℃ and 40% humidity, conveying the candies pressed by the pelleting press to a rolling cage by using a conveying belt, and setting for 1h to obtain pressed candies;
(5) and (3) drying: and (5) slightly turning the pressed candy obtained in the step (4) for 1 time every 2 hours, and carrying out ventilation drying for more than 10 hours to obtain the composite gel candy.
Example 3
The embodiment provides a composite gel candy which is prepared by mixing the following components in parts by mass: 252 parts of gelatin, 122 parts of glycerol, 252 parts of purified water, 12 parts of maltitol, 70 parts of camellia oil, 20 parts of pecan oil, 15 parts of theaflavin, 115 parts of catechin, 3 parts of rosemary oil, 30 parts of safflower seed oil, 3 parts of zanthoxylum oil, 30 parts of linseed oil, 3 parts of ginger oil and 12 parts of beeswax.
The preparation method of the composite gel candy comprises the following steps:
(1) pretreatment of raw materials: uniformly mixing theaflavin and catechin, and sieving with 100 mesh sieve to obtain powder for later use; uniformly mixing the pecan oil, the rosemary oil, the zanthoxylum oil, the safflower seed oil and the ginger oil to obtain standby mixed oil;
(2) preparing gel liquid: dissolving maltitol with one third of purified water for standby, mixing glycerol and the rest purified water, heating, decocting and stirring the dissolved maltose, adding gelatin when the temperature is 70 ℃, continuously heating to 75 ℃, keeping the temperature and stirring for about 1 hour, vacuumizing to 0.06Mpa to remove bubbles, vacuumizing for about 30 minutes, then discharging air, filtering by a 80-mesh sieve, standing for 4 hours to prepare gel liquid, and keeping the temperature at 50 ℃ for standby;
(3) preparing capsule core feed liquid: heating linseed oil to 75 ℃, starting a stirring paddle, adding beeswax, continuing stirring for 5 minutes after the beeswax is completely dissolved, adding camellia oil, cooling to about 45 ℃, mixing with the standby mixed oil prepared in the step (1), stirring for 15 minutes, mixing with the standby powder prepared in the step (1), stirring for 25 minutes, vacuumizing to-0.06 MPa, and removing bubbles to obtain capsule core feed liquid for standby;
(4) and (3) pressing and forming: debugging a pelleting press, pouring a mold, injecting a core material, measuring the difference of pills to be in accordance with 1 +/-7.5%, checking that the thickness of two sides of an appearance rubber is consistent, the interface is firm, checking once every 60min, conveying the gel liquid prepared in the step (2) and the capsule core material liquid prepared in the step (3) to the pelleting press under the conditions of the temperature of 18 ℃ and the humidity of 30%, conveying candies pressed by the pelleting press to a rolling cage by using a conveying belt, and setting for 1h to obtain pressed candies;
(5) and (3) drying: and (5) slightly turning the pressed candy obtained in the step (4) for 1 time every 2 hours, and carrying out ventilation drying for more than 10 hours to obtain the composite gel candy.
Example 4
The embodiment provides a composite gel candy which is prepared by mixing the following components in parts by mass: 380 parts of gelatin, 128 parts of glycerol, 280 parts of purified water, 18 parts of maltitol, 90 parts of camellia oil, 40 parts of pecan oil, 40 parts of theaflavin, 140 parts of catechin, 8 parts of rosemary oil, 40 parts of safflower seed oil, 8 parts of zanthoxylum oil, 40 parts of linseed oil, 8 parts of ginger oil and 18 parts of beeswax.
The preparation method of the composite gel candy comprises the following steps:
(1) pretreatment of raw materials: uniformly mixing theaflavin and catechin, and sieving with 100 mesh sieve to obtain powder for later use; uniformly mixing the pecan oil, the rosemary oil, the zanthoxylum oil, the safflower seed oil and the ginger oil to obtain standby mixed oil;
(2) preparing gel liquid: dissolving maltitol in half of purified water for standby, mixing glycerol with the rest purified water, heating, decocting and stirring the dissolved maltose, adding gelatin when the temperature is 70 ℃, continuously heating to 75 ℃, keeping the temperature and stirring for about 1 hour, vacuumizing to 0.08Mpa to remove bubbles, vacuumizing for about 30 minutes, then discharging air, filtering by 80 meshes, standing for 6 hours to obtain gel liquid, and keeping the temperature at 60 ℃ for standby;
(3) preparing capsule core feed liquid: heating linseed oil to 75 ℃, starting a stirring paddle, adding beeswax, continuing stirring for 5 minutes after the beeswax is completely dissolved, adding camellia oil, cooling to about 45 ℃, mixing with the standby mixed oil prepared in the step (1), stirring for 15 minutes, mixing with the standby powder prepared in the step (1), stirring for 25 minutes, vacuumizing to-0.08 MPa, and removing bubbles to obtain capsule core feed liquid for standby;
(4) and (3) pressing and forming: debugging a pelleting press, pouring a mold, injecting a core material, measuring the difference of pills to be in accordance with 1 +/-7.5%, checking that the thickness of two sides of an appearance rubber is consistent, the interface is firm, checking once every 60min, conveying the gel liquid prepared in the step (2) and the capsule core material liquid prepared in the step (3) to the pelleting press under the conditions of 24 ℃ and 40% humidity, conveying the candies pressed by the pelleting press to a rolling cage by using a conveying belt, and setting for 1h to obtain pressed candies;
(5) and (3) drying: and (5) slightly turning the pressed candy obtained in the step (4) for 1 time every 2 hours, and carrying out ventilation drying for more than 10 hours to obtain the composite gel candy.
Example 5
The embodiment provides a composite gel candy which is prepared by mixing the following components in parts by mass: 255 parts of gelatin, 122.40 parts of glycerol, 255 parts of purified water, 15 parts of maltitol, 80 parts of camellia oil, 30 parts of pecan oil, 20 parts of theaflavin, 120 parts of catechin, 5 parts of rosemary oil, 30 parts of safflower seed oil, 5 parts of zanthoxylum oil, 35 parts of linseed oil, 5 parts of ginger oil and 15 parts of beeswax.
The preparation method of the composite gel candy comprises the following steps:
(1) pretreatment of raw materials: uniformly mixing theaflavin and catechin, and sieving with 100 mesh sieve to obtain powder for later use; uniformly mixing the pecan oil, the rosemary oil, the zanthoxylum oil, the safflower seed oil and the ginger oil to obtain standby mixed oil;
(2) preparing gel liquid: dissolving maltitol in purified water of two fifths for use, mixing glycerol with the rest purified water, heating, decocting and stirring the dissolved maltose, adding gelatin at 70 deg.C, heating to 75 deg.C, stirring for 1 hr, vacuumizing to-0.07 Mpa to remove bubbles, vacuumizing for 30 min, degassing, filtering with 80 mesh, standing for 5 hr to obtain gel solution, and keeping the temperature at 55 deg.C;
(3) preparing capsule core feed liquid: heating linseed oil to 75 ℃, starting a stirring paddle, adding beeswax, continuing stirring for 5 minutes after the beeswax is completely dissolved, adding camellia oil, cooling to about 45 ℃, mixing with the standby mixed oil prepared in the step (1), stirring for 15 minutes, mixing with the standby powder prepared in the step (1), stirring for 25 minutes, vacuumizing to-0.07 MPa, and removing bubbles to obtain capsule core feed liquid for standby;
(4) and (3) pressing and forming: debugging a pelleting press, pouring a mold, injecting a core material, measuring the difference of pills to be in accordance with 1 +/-7.5%, checking that the thickness of two sides of an appearance rubber is consistent, the interface is firm, checking once every 60min, conveying the gel liquid prepared in the step (2) and the capsule core material liquid prepared in the step (3) to the pelleting press under the conditions of temperature of 20 ℃ and humidity of 35%, conveying candies pressed by the pelleting press to a rolling cage by using a conveying belt, and setting for 1h to obtain pressed candies;
(5) and (3) drying: and (5) slightly turning the pressed candy obtained in the step (4) for 1 time every 2 hours, and carrying out ventilation drying for more than 10 hours to obtain the composite gel candy.
The key process control points of the preparation method are as follows:
1. sugar dissolving: heating maltitol to be completely dissolved;
2. controlling the temperature of gelatin, and adding gelatin at about 70 deg.C; after the glue is added, the temperature is controlled to be about 75 ℃, and the stirring is carried out for about 1 hour;
3. vacuumizing to control the vacuum degree (-0.06-0.08) Mpa for about 30 minutes;
4. pressing and shaping;
5. controlling the loading in the pressing process, wherein the loading difference limit is +/-7.5%;
6. controlling the temperature of an operation chamber to be 18-24 ℃ and the relative humidity to be 30-40 percent;
7. a drying procedure: drying for more than 10 hours. The candy is turned over in time to prevent the candy from being adhered;
8. and (4) lamp inspection: and (4) placing the dried candies on a light inspection machine, manually selecting unqualified candies, and packaging the qualified candies.
Comparative example 1
The only difference between this comparative example and example 3 is that: and (2) adding gelatin at 70 ℃, and continuously stirring for 1 hour.
Comparative example 2
The only difference between this comparative example and example 3 is that: and (4) temperature and humidity control is not carried out, and the temperature and the humidity are randomly measured, wherein the measured temperature is 15 ℃ and the measured humidity is 45%.
Sensory evaluation test
The test method comprises the following steps: by using the methods of examples 1-5 and comparative examples 1-2, the capsule skin flatness, color and taste of the produced composite gel candy are subjected to sensory evaluation, and the results are shown in table 1:
TABLE 1 sensory evaluation results of Compound gel candies
As can be seen from the above table, the gel liquid is not heated and stirred, so that the flatness of the surface of the capsule shell is influenced; meanwhile, the temperature and humidity are not accurately ensured during pelleting, and the leveling of the capsule shell and the appearance of the pellet are greatly influenced during pelleting, so that the control points need to be paid more attention. And for the embodiments 1-5 with continuous conditions, the appearance and the taste of the finished product can be stably ensured.
The above description is only for the specific embodiments of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art can easily conceive of the changes or substitutions within the technical scope of the present invention, and all the changes or substitutions should be covered within the scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the protection scope of the appended claims.
Claims (10)
1. The composite gel candy is characterized by being prepared by mixing the following components in parts by mass: 250-300 parts of gelatin, 120-130 parts of glycerol, 250-300 parts of purified water, 10-20 parts of maltitol, 50-100 parts of camellia oil, 10-50 parts of pecan oil, 10-50 parts of theaflavin, 100-150 parts of catechin, 1-10 parts of rosemary oil, 20-50 parts of safflower seed oil, 1-10 parts of zanthoxylum oil, 20-50 parts of linseed oil, 1-10 parts of ginger oil and 10-20 parts of beeswax.
2. The compound gel candy as claimed in claim 1, which is prepared by mixing the following components in percentage by mass: 252-260 parts of gelatin, 122-128 parts of glycerol, 252-280 parts of purified water, 12-18 parts of maltitol, 70-90 parts of camellia oil, 20-40 parts of pecan oil, 15-40 parts of theaflavin, 115-140 parts of catechin, 3-8 parts of rosemary oil, 25-40 parts of safflower seed oil, 3-8 parts of zanthoxylum oil, 30-40 parts of linseed oil, 3-8 parts of ginger oil and 12-18 parts of beeswax.
3. The compound gel candy as claimed in claim 1, which is prepared by mixing the following components in percentage by mass: 255 parts of gelatin, 122.40 parts of glycerol, 255 parts of purified water, 15 parts of maltitol, 80 parts of camellia oil, 30 parts of pecan oil, 20 parts of theaflavin, 120 parts of catechin, 5 parts of rosemary oil, 30 parts of safflower seed oil, 5 parts of zanthoxylum oil, 35 parts of linseed oil, 5 parts of ginger oil and 15 parts of beeswax.
4. The composite gel confection of claim 1, wherein said theaflavins are of 40% purity.
5. The composite gel confection of claim 1, wherein the catechin has a purity of 80%.
6. The method for preparing the composite gel candy as claimed in claim 1, which is characterized by comprising the following steps:
(1) pretreatment of raw materials: uniformly mixing theaflavin and catechin, and sieving with 100 mesh sieve to obtain powder for later use; uniformly mixing the pecan oil, the rosemary oil, the zanthoxylum oil, the safflower seed oil and the ginger oil to obtain standby mixed oil;
(2) preparing gel liquid: adding one third to one half of purified water into maltitol to dissolve for later use, mixing glycerol and the rest of purified water, heating, boiling and stirring the dissolved maltose, adding gelatin when the temperature is 70 ℃, continuously heating to 75 ℃, keeping the temperature and stirring for about 1 hour, vacuumizing to 0.06-0.08 Mpa to remove bubbles, vacuumizing for about 30 minutes, then discharging air, standing for 4-6 hours to prepare gel liquid, and keeping the temperature at 50-60 ℃ for later use;
(3) preparing capsule core feed liquid: heating linseed oil to 75 ℃, starting a stirring paddle, adding beeswax, continuing stirring for 5 minutes after the beeswax is completely dissolved, adding camellia oil, cooling to about 45 ℃, mixing with the standby mixed oil prepared in the step (1), stirring for 15 minutes, mixing with the standby powder prepared in the step (1), stirring for 25 minutes, vacuumizing to-0.06-0.08 MPa, and removing bubbles to obtain capsule core feed liquid for standby;
(4) and (3) pressing and forming: conveying the gel liquid prepared in the step (2) and the capsule core liquid prepared in the step (3) to a pelleting press under the conditions that the temperature is 18-24 ℃ and the humidity is 30-40%, conveying the candies extruded by the pelleting press to a rolling cage by using a conveying belt, and shaping for 1h to obtain extruded candies;
(5) and (3) drying: and (4) carrying out ventilation drying on the pressed candy obtained in the step (4) for more than 10 hours to obtain the composite gel candy.
7. The preparation method of the compound gel candy as claimed in claim 6, wherein the preparation process method comprises the following steps:
(1) pretreatment of raw materials: uniformly mixing theaflavin and catechin, and sieving with 100 mesh sieve to obtain powder for later use; uniformly mixing the pecan oil, the rosemary oil, the zanthoxylum oil, the safflower seed oil and the ginger oil to obtain standby mixed oil;
(2) preparing gel liquid: dissolving maltitol in purified water of two fifths for use, mixing glycerol with the rest purified water, heating, decocting and stirring the dissolved maltose, adding gelatin at 70 deg.C, heating to 75 deg.C, stirring for 1 hr, vacuumizing to-0.07 Mpa to remove bubbles, vacuumizing for 30 min, discharging gas, standing for 5 hr to obtain gel solution, and keeping at 55 deg.C;
(3) preparing capsule core feed liquid: heating linseed oil to 75 ℃, starting a stirring paddle, adding beeswax, continuing stirring for 5 minutes after the beeswax is completely dissolved, adding camellia oil, cooling to about 45 ℃, mixing with the standby mixed oil prepared in the step (1), stirring for 15 minutes, mixing with the standby powder prepared in the step (1), stirring for 25 minutes, vacuumizing to-0.07 MPa, and removing bubbles to obtain capsule core feed liquid for standby;
(4) and (3) pressing and forming: conveying the gel liquid prepared in the step (2) and the capsule core liquid prepared in the step (3) to a pelleting press under the conditions of temperature of 20 ℃ and humidity of 35%, conveying the candies extruded by the pelleting press to a rolling cage by using a conveying belt, and shaping for 1h to obtain extruded candies;
(5) and (3) drying: and (4) carrying out ventilation drying on the pressed candy obtained in the step (4) for more than 10 hours to obtain the composite gel candy.
8. The method for preparing a composite gel candy as claimed in claim 6, wherein the gel liquid is filtered by 80 mesh after the air is discharged in step (2).
9. The method for preparing a compound gel candy as claimed in claim 6, wherein before step (4), the pelleting press is adjusted, the difference between the cast and the filled material is measured to be 1 ± 7.5%, the thickness of the two sides of the appearance gum skin is checked to be consistent, the interface is firm, and the check is performed every 60 min.
10. The method for preparing a composite gel candy as claimed in claim 6, wherein the drying process of step (5) is performed by slightly turning the gel candy 1 time every 2 hours.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010490046.1A CN111567661A (en) | 2020-06-02 | 2020-06-02 | Composite gel candy and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010490046.1A CN111567661A (en) | 2020-06-02 | 2020-06-02 | Composite gel candy and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111567661A true CN111567661A (en) | 2020-08-25 |
Family
ID=72116058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010490046.1A Pending CN111567661A (en) | 2020-06-02 | 2020-06-02 | Composite gel candy and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111567661A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112841379A (en) * | 2021-02-01 | 2021-05-28 | 武汉海奥圣医疗科技股份有限公司 | Casein polypeptide gel candy and preparation method thereof |
CN112841380A (en) * | 2021-02-20 | 2021-05-28 | 姚礼群 | Gel candy and preparation method thereof |
CN113383848A (en) * | 2021-04-28 | 2021-09-14 | 施发塘 | Gel candy based on camellia oil and peony seed oil and preparation method thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108685006A (en) * | 2018-05-31 | 2018-10-23 | 杭州天龙健康产品有限公司 | A kind of 3 solid beverage of omega |
CN109938147A (en) * | 2019-03-29 | 2019-06-28 | 江西美好时光生物科技有限公司 | A kind of low sugar DHA gel candy improving memory and strengthen immunity |
CN110140796A (en) * | 2019-05-16 | 2019-08-20 | 湖南尔康保健食品有限公司 | A kind of quick-fried pearl sugar and preparation method thereof |
-
2020
- 2020-06-02 CN CN202010490046.1A patent/CN111567661A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108685006A (en) * | 2018-05-31 | 2018-10-23 | 杭州天龙健康产品有限公司 | A kind of 3 solid beverage of omega |
CN109938147A (en) * | 2019-03-29 | 2019-06-28 | 江西美好时光生物科技有限公司 | A kind of low sugar DHA gel candy improving memory and strengthen immunity |
CN110140796A (en) * | 2019-05-16 | 2019-08-20 | 湖南尔康保健食品有限公司 | A kind of quick-fried pearl sugar and preparation method thereof |
Non-Patent Citations (1)
Title |
---|
郑笑男;: "茶多酚抗氧化功能及保护实验性肝损伤作用的研究进展", 临床合理用药杂志, no. 29, 30 May 2011 (2011-05-30) * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112841379A (en) * | 2021-02-01 | 2021-05-28 | 武汉海奥圣医疗科技股份有限公司 | Casein polypeptide gel candy and preparation method thereof |
CN112841380A (en) * | 2021-02-20 | 2021-05-28 | 姚礼群 | Gel candy and preparation method thereof |
CN113383848A (en) * | 2021-04-28 | 2021-09-14 | 施发塘 | Gel candy based on camellia oil and peony seed oil and preparation method thereof |
WO2022227149A1 (en) * | 2021-04-28 | 2022-11-03 | 施发塘 | Camellia oil and peony seed oil-based gelatin candy and preparation method therefor |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105341185A (en) | Composite nutritional blend oil and preparation method thereof | |
CN111567661A (en) | Composite gel candy and preparation method thereof | |
CN105727081A (en) | Healthcare product composition for treating gout | |
CN103859379A (en) | Formula and preparation method of life cultivation and health preservation food helpful for improving memory | |
CN104286273A (en) | Application of dendrobium candidum and tea leaf product thereof | |
CN104286272A (en) | Application of dendrobium candidum flowers and tea leaf product thereof | |
JP2018510641A (en) | Health supplements for hair growth promotion, hair loss relief and improvement, blood sugar control, gastrointestinal symptom relief and improvement | |
KR101483255B1 (en) | Korean Herb Tea composing of extract from Spring onion root and Method preparing thereof | |
CN113855735A (en) | Composition for promoting metabolic digestion and preparation method thereof | |
CN105249440A (en) | Donkey-hide gelatin cake | |
CN112869073A (en) | Chinese medicinal composition comprising fruits and vegetables for improving human body function and removing harmful toxin, and its preparation method | |
Saad | Greco-Arab and Islamic diet therapy: Tradition, research and practice | |
CN105981853A (en) | Nutritional function enriched mild warm tea drink recipe | |
CN112841380A (en) | Gel candy and preparation method thereof | |
KR20180056199A (en) | Manufacturing method of gum for diet containing Moringa Oleifera extract | |
CN102326655A (en) | Green healthcare longevity fruit | |
CN110679935A (en) | Burdock and ginseng essence cream and preparation method thereof | |
KR100488512B1 (en) | healthy foodstuffs mainly including seed oil of evening primrose and the composion thereof | |
KR100815333B1 (en) | Healthfood using medicalherbs and method preparing thereof | |
WO2018072341A1 (en) | Pharmaceutical agent for treating aids or tumor by means of oral administration and external application in combination | |
CN110651983A (en) | High-protein nutrition powder and preparation method thereof | |
CN109480280A (en) | A kind of draft flowers and fruits heart and brain relax fully nutrient and preparation method | |
CN109289017A (en) | For clearing up the composition and preparation method of blood vessel and blood | |
CN110050911A (en) | Five-cereal health-care dew | |
CN107788185A (en) | A kind of radish pollen tea and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |